# China NMPA Drug Inspection - Leshan Geriatric Specialist Hospital - Hawthorn Capsules

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/leshan-geriatric-specialist-hospital/6cad85fd-3b32-4683-bb16-94107a0f0443/
Source feed: China

> China NMPA drug inspection for Leshan Geriatric Specialist Hospital published October 08, 2021. Drug: Hawthorn Capsules. In an announcement dated October 8, 2021, the Sichuan Provincial Drug Administration identified quality failures in thre

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Sichuan Provincial Drug Administration Announcement Regarding 3 Batches of Drugs Not Meeting Regulations (No. 12 of 2021)
- Company Name: Leshan Geriatric Specialist Hospital
- Publication Date: 2021-10-08
- Drug Name: Hawthorn Capsules
- Inspection Finding: Moisture content and fill weight discrepancies do not meet regulations
- Action Taken: Relevant enterprises and units are required to take risk control measures such as suspending sales and use, and recalling products; investigate the reasons for non-compliance and make effective rectifications; organize investigations and make public the results of the investigations.
- Summary: In an announcement dated October 8, 2021, the Sichuan Provincial Drug Administration identified quality failures in three drug batches across different entities. The involved organizations include Sichuan Tongshantang Traditional Chinese Medicine Pieces Co., Ltd., Chongqing Kerui Pharmaceutical (Group) Co., Ltd., and Leshan Geriatric Hospital. The inspections, conducted by regional testing centers, uncovered several quality issues. Sichuan Tongshantang’s Rubia cordifolia failed due to poor physical appearance and the presence of medicinal residue or impurities. Chongqing Kerui Pharmaceutical’s Chenxianglu Bailu Pian was flagged for weight variation, while the Hawthorn Capsules from Leshan Geriatric Hospital failed regarding moisture content and fill weight consistency. Following the 'Drug Administration Law of the People's Republic of China,' the regulatory authority has ordered the companies to suspend sales, halt the use of these products, and initiate immediate recalls. Furthermore, the companies must investigate the root causes of these failures and implement corrective actions. Local regulatory departments are also tasked with investigating potential illegal activities regarding the production and sale of substandard drugs, ensuring that the results are publicly disclosed to maintain pharmaceutical safety standards.

Company: https://www.globalkeysolutions.net/companies/leshan-geriatric-specialist-hospital/1065cd65-4619-4a72-b94d-f04616ace2f8/